Cliff Asness's TOI Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 48,597 shares of The Oncology Institute, Inc. (TOI) worth $263,882, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 4 quarters.
Based on 13F filings, Cliff Asness has maintained this position in TOI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 4,078 shares. Largest reduction occurred in Q1 2026, reducing 3,553 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's The Oncology Institute (TOI) Holding Value Over Time
Track share changes against reported price movement
Quarterly The Oncology Institute (TOI) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +4,078 | Add 9.16% | 48,597 | $5.43 |
| Q1 2026 | -3,553 | Reduce 7.39% | 44,519 | $3.07 |
| Q4 2025 | +4,007 | Add 9.09% | 48,072 | $3.56 |
| Q3 2025 | +44,065 | New Buy | 44,065 | $3.49 |
Cliff Asness's The Oncology Institute Investment FAQs
Cliff Asness first purchased The Oncology Institute, Inc. (TOI) in Q3 2025, acquiring 44,065 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held The Oncology Institute, Inc. (TOI) for 4 quarters since Q3 2025.
Cliff Asness's largest addition to The Oncology Institute, Inc. (TOI) was in Q3 2025, adding 44,065 shares worth $153,786.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 48,597 shares of The Oncology Institute, Inc. (TOI), valued at approximately $263,882.
As of the Q2 2026 filing, The Oncology Institute, Inc. (TOI) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in The Oncology Institute, Inc. (TOI) was 48,597 shares, as reported at the end of Q2 2026.